.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD19_LinagliptinAndEmpagliflo.LinagliptinAndEmpagliflo .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD19_LinagliptinAndEmpagliflo.LinagliptinAndEmpagliflo| name: | LinagliptinAndEmpagliflozin | |
| ATC code: | A10BD19 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 5 | mg |
| volume of distribution: | 112 | L |
| clearance: | 70 | L/h |
| other parameters in model implementation | ||
Linagliptin and empagliflozin is a fixed-dose combination of two oral antidiabetic agents: linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The combination is approved for the treatment of type 2 diabetes mellitus to improve glycemic control in adults.
Estimated pharmacokinetic parameters for healthy adults based on separate data for linagliptin and empagliflozin. No existing publication reports full combined fixed-dose PK parameters as of knowledge cutoff.